ECM
SGMO

Element Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Element Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,631
Closed -$240K – 981
2018
Q1 		$240K Buy
+12,631
New +$270K 0.01% 590

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Element Capital Management's SGMO Position: Q2 2018 in Review

Element Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 12,631 shares — an estimated $240K sold.

Element Capital Management first reported a position in SGMO in Q1 2018 and held it in 1 quarter. The position peaked at $240K in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • Element Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 12,631 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $240K.
  • Element Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 1 quarter.
  • Element Capital Management's SANGAMO THERAPEUTICS INC position peaked at $240K in Q1 2018.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.